Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
Where we began and why there’s no end in sight.

MediBeacon, in a management buyout in 2012, acquired technology from Mallinckrodt/Covidien. Since then, the company has conducted numerous clinical studies focused on the transdermal detection of proprietary fluorescent agents as a means to measure physiological function.

The company’s intellectual property has expanded substantially and now includes over 40 granted US patents, which cover composition of matter of the company’s pharmaceuticals, as well as algorithms and methods related to the transdermal detection of these patented fluorescent agents.


In 2015, Pansend Life Sciences of INNOVATE Corp. (NYSE: VATE) became the largest equity investor in MediBeacon. In 2019, MediBeacon entered into a $30 million investment and exclusive commercialization partnership in Greater China with Huadong Medicine Co., Ltd. Huadong is a leading China-based pharmaceutical company listed on the Shenzhen Stock Exchange.

MediBeacon’s fluorescent agent platform for use in physiological function monitoring has important applications in kidney health, gastrointestinal health, and beyond.

Making technology that is making medical history.*
  • The Transdermal GFR Measurement System (TGFR) is poised to begin its pivotal clinical study in the U.S. and Europe.
  • First-in-human studies are underway to establish the feasibility of fluorescent tracer agent-based systems to quantify the permeability of the gastrointestinal tract in patients with active Crohn’s Disease.
  • The Centers for Medicare & Medicaid Services implement a dedicated ICD-10 code for use with the TGFR (XT25XE5 - Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology, Group 5)
  • MediBeacon enters into a $30 Million investment and exclusive commercialization partnership with Huadong Medicine headquartered in greater China.
  • MediBeacon obtains ISO 13485:2016 Recertification.
  • Introduction of the Transdermal Mini GFR Monitor for preclinical use.
  • FDA grants “Breakthrough Device Status” for MediBeacon’s Transdermal GFR Measurement System.
  • Publication of MediBeacon gut permeability research in Nature Publication – Scientific Reports.
  • Clinical studies demonstrating TGFR use completed on patients with impaired kidney function.
  • MediBeacon presents gastrointestinal permeability research at Digestive Disease Week in Chicago.
  • MediBeacon acquires Mannheim Pharma & Diagnostics (Preclinical business).
  • NIH awards grant to study fluorescent technology for use in ocular angiography.
  • A follow-on grant from the Bill & Melinda Gates Foundation funds MediBeacon continued gastroenterology collaboration with Washington University School of Medicine.
  • Investment in patented fluorescent tracer agents for use in numerous potential medical applications outside of nephrology increases.
  • MediBeacon closes on a $22.4 million staged financing with Pansend Life Sciences, LLC.
  • Results of initial TGFR clinical studies presented at American Society of Nephrology (ASN) Kidney Week.
  • Initial TGFR clinical studies are completed at the University of Maryland.
  • MediBeacon in collaboration with Washington University begins pursuing the use of fluorophore technology in gastroenterology. The work is funded by an initial grant from the Bill & Melinda Gates Foundation.
  • MediBeacon begins human clinical studies at the University of Maryland.
  • MediBeacon acquires outright all technology, market research, patent estate and other related assets from Mallinckrodt.
  • First quarter 2012, U.S. patent issued to MediBeacon for Lumitrace™ (relmapriazin).

At MediBeacon, we measure our success in our ability to create measurable differences that impact global health. Evidence of our advances can be found in the numerous issued global patents.